Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases

E-ISSN： 1873-4286|18|7|875-883

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.18, Iss.7, 2012-03, pp. : 875-883

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sigma-1 Receptor Chaperones and Diseases

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 9, Iss. 3, 2009-09 ,pp. : 184-189

Bentham Science Publishers

Access to resources Recommend Favorite

Dopamine D1 receptor agonists as antiparkinson drugs

By Mailman R.B. Nichols D.E.

Trends in Pharmacological Sciences, Vol. 19, Iss. 7, 1998-07 ,pp. : 255-256

Elsevier

Access to resources Recommend Favorite

A₁ adenosine receptor agonists and their potential therapeutic applications

By Elzein Elfatih Zablocki Jeff

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 12, 2008-12 ,pp. : 1901-1910

Informa Healthcare

Access to resources Recommend Favorite

Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands

Current Neuropharmacology, Vol. 6, Iss. 4, 2008-12 ,pp. : 344-366

Bentham Science Publishers

Access to resources Recommend Favorite

7 Nicotinic Receptor Agonists as Potential Therapeutic Drugs for Schizophrenia

Current Medicinal Chemistry - Central Nervous System Agents, Vol. 5, Iss. 3, 2005-09 ,pp. : 171-184

Bentham Science Publishers

Access to resources Recommend Favorite